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We report here the discovery and characterization
of a gene, ELABELA (ELA), encoding a conserved
hormone of 32 amino acids. Present in human em-
bryonic stem cells, ELA is expressed at the onset of
zebrafish zygotic transcription and is ubiquitous in
the naive ectodermal cells of the embryo. Using
zinc-finger-nuclease-mediated gene inactivation in
zebrafish, we created an allelic series of elamutants.
ela null embryos have impaired endoderm differenti-
ation potential marked by reduced gata5 and sox17
expression. Loss of Ela causes embryos to develop
with a rudimentary heart or no heart at all, surpris-
ingly phenocopying the loss of the apelin receptor
(aplnr), which we show serves as Ela’s cognate G
protein-coupled receptor. Our results reveal the exis-
tence of a peptide hormone, ELA, which, together
with APLNR, forms an essential signaling axis for
early cardiovascular development.
INTRODUCTION
Hormonal peptides are an important class of secreted signaling
molecules. Endogenous peptides are most notable for their
functions in innate defense as antimicrobial peptides (Cederlund
et al., 2011), in immune regulation as chemokines (Bonecchi
et al., 2009), and in modulation of behavior as neuropeptides
(van den Pol, 2012). Deficiencies in hormonal peptides are the
cause of several human diseases, the most prominent being
the loss of insulin or insulin resistance in diabetes mellitus.
Deficiency in the neuropeptide hypocretin causes narcolepsy
(Nishino et al., 2000; Peyron et al., 2000), and anomalies in regu-
lation of the appetite and satiety hormones leptin (Montague
et al., 1997) and ghrelin are the underlying causes of congenital
obesity and hyperphagia in Prader-Willi syndrome (Cummings
et al., 2002).
Whereas many peptide hormones have been characterized
and shown to play key roles in adult physiology, an involvement
of these tiny signaling molecules during early development has
not been established. During embryogenesis, six key signaling
pathways (WNT, BMP/NODAL, FGF/IGF, NOTCH, HEDGEHOG,
and HIPPO) are crucial for embryonic patterning. To our knowl-672 Developmental Cell 27, 672–680, December 23, 2013 ª2013 Elsedge, no hormonal peptide has yet been implicated in the ability
of naive blastomeres to differentiate into one of the three embry-
onic germ layers.
We have isolated a human gene, AK092578, which is
currently annotated as a noncoding transcript. This gene is
predicted to encode a 54 aa hormone with a signal peptide.
We named this hormone, which is present in all vertebrate
species, ELABELA (ELA). ELA expression has been reported
to be rapidly downregulated during human embryonic stem
cell (hESC) differentiation (Miura et al., 2004). To our knowledge,
the second-earliest peptide hormone to be expressed during
embryogenesis is apelin (APLN), the transcription of which be-
gins during gastrulation in mice (D’Aniello et al., 2009). However,
Apln knockout mice have no defects in early embryonic
development (Kuba et al., 2007), which is inconsistent with the
inactivation of its G protein-coupled receptor (GPCR) Aplnr
(also known as Apj or Agtrl1), the loss of which leads to variable
embryonic lethality due to growth retardation and cardiac
malformations (Charo et al., 2009). In zebrafish, mutations in
the APLNR homolog aplnrb impair the migration of cardiac pro-
genitors from the lateral plate mesoderm into the heart field.
Because aplnra and aplnrb are expressed in early precursors
of the endodermal lineage, hours before the onset of apln
expression, it has been postulated that APLNR transduces the
signal of an earlier, yet to be discovered hormone (Charo
et al., 2009; Scott et al., 2007).
Here, we demonstrate that ELA is a secreted peptide hor-
mone. Using zinc-finger-nuclease (ZFN)-mediated gene inacti-
vation, we created an allelic series of ela null zebrafish, and
show that it is essential for endoderm differentiation and heart
morphogenesis. We find that Ela, and not Apln, is the earliest
ligand recognized by Aplnr, which mediates its effect on endo-
derm differentiation and subsequent cardiogenesis. Together,
our results show the existence of an unannotated hormone,
ELA, which is critical in vivo for heart morphogenesis that signals
through the APLNR pathway.RESULTS
ELA Is a Conserved Hormone
Human ELA consists of three exons on chromosome 4, which
generates a transcript (AK092578) that is annotated as a non-
coding RNA. However, ELA mRNA contains a conserved open
reading frame (ORF) that encodes a predicted polypeptide of
54 aa. Phylogenetic analysis revealed that this polypeptide isevier Inc.
Figure 1. ELA Encodes a Conserved
Hormone
(A) ELA encodes a conserved vertebrate protein of
54 aa consisting of a secretory signal and amature
32 aa peptide. The carboxy terminus is invariant.
White arrowhead: predicted signal peptide cleav-
age site between G22 and Q33. Black double
arrowheads: possible furin cleavage sites after
conserved di-arginines R31R32 and R42R43
motifs. The N- and C-terminal epitopes chosen for
a N and a C antibody production are noted. The a
C antibody is designed to recognize all ELA pep-
tides regardless of species.
(B) ELA, like POU5F1, is rapidly silenced in hESCs
during embryoid body differentiation (data are
represented as mean ± SEM).
(C) By immunofluorescence in hESCs, endoge-
nous ELA marked with the a C antibody coloc-
alizes with the trans-Golgi network marked by
TGN46.
(D) Western blot for ELA, which is translated,
processed, secreted, and recognized by the a C
antibody as a 4 kDa single band when overex-
pressed in Xenopus laevis embryos. BFA-medi-
ated inhibition of secretion blocks ELA processing.
(E) The a C antibody recognizes both full-length
ELA and processed ELA, whereas the a N anti-
body is specific to the mature processed ELA
peptide.
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sequence of 22 residues (Figure 1A). Along with a pair of
conserved cysteines, the last 13 residues are nearly invariant
in all vertebrate species. Based on this prediction, we raised an-
tibodies against the N and C termini of the predicted mature
ELA peptide (hereafter referred to as a N and a C antibodies;
Figure 1A). ELA is most highly expressed in undifferentiated
hESCs and is rapidly downregulated during differentiation (Fig-
ure 1B), as previously reported (Miura et al., 2004). In hESCs,
the a C antibody detects ELA in the Golgi apparatus, as evi-
denced by colocalization with TGN46, a trans-Golgi marker
(Figure 1C), suggesting that ELA is in the secretory pathway.
To confirm that ELA is processed for secretion, human ELA
ORF mRNA was microinjected into 4-cell-stage Xenopus laevis
embryos. After 10 hr of secretion, we confirmed that ELA wasDevelopmental Cell 27, 672–680, Dtranslated, processed, and secreted by
embryos (Figure 1D). In the supernatant,
the processed ELA was the same size as
a synthetically produced recombinant
ELA consisting of the C-terminal 32
residues. Increasing amounts of Brefel-
din A (BFA), an antibiotic that blocks
the exit of secretory proteins from the
endoplasmic reticulum, was able to
block ELA processing and secretion (Fig-
ure 1D). Unlike the a C antibody, which
recognizes both full-length and pro-
cessed ELA, the a N antibody was spe-
cific to mature ELA, indicating that its
epitope is revealed once the signal
peptide is cleaved (Figure 1E). Takentogether, these data confirm that ELA encodes a potentially
soluble mature peptide with a molecular weight of <4 kDa.
Creating an Allelic Series of ela Mutants in Zebrafish
During zebrafish embryogenesis, ela is expressed from the mid-
blastula transition (MBT) to 3 days postfertilization (dpf; Figures
2A and 2B). Without any measurable maternal contribution, ela
is ubiquitous in dividing cells of the blastoderm before becoming
restricted after gastrulation to axial structures, with most prom-
inent expression in the neural tube (Figure 2A). ela is located
on chromosome 1 and also consists of three exons (Figure 2C).
To document the exact function of and requirement for ela in vivo,
we designed and injected custom ZFNs to induce double-
stranded breaks in exon 1 of ela, which codes for its signal pep-
tide. Screening of the F1 generation allowed us to identify anecember 23, 2013 ª2013 Elsevier Inc. 673
Figure 2. Generation of an Allelic Series of Mutant ela Zebrafish
(A) By WISH in zebrafish embryos, ela is found to be zygotically expressed and ubiquitous in the blastoderm. During gastrulation, its expression becomes axial
and is strongest in the neural tube.
(B) RT-PCR analysis shows that, relative to actin, expression of ela is exclusively zygotic, peaking at 100% epiboly and becoming absent by 4 dpf.
(C) In zebrafish, ela consists of three exons located on chromosome 1. A custom pair of ZFNs targeting exon 1 of ela was used to create an allelic series of
mutations within the signal peptide of Ela.
(D) Three distinct loss-of-function alleles were generated. The elabr21allele results in a unique 7 aa in-frame deletion in Ela’s signal peptide. Alleles elabr13 and
elabr15 caused premature stop codons and disrupted the reading frame, resulting in no Ela mature peptide.
(E) Relative to WT embryos, homozygous null elabr13 embryos show defective epiboly movements and a constricted germ ring at the involuting margin at 70%
epiboly.
(F) RT-PCR reveals that at 100% epiboly, endogenous ela and elabr13 mRNAs are of a distinct size. Western blotting using the a C antibody shows that
endogenous Ela is recognized in WT embryos and is absent in null elabr13 siblings.
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Ela, a Ligand for Aplnrallelic series (Figure 2D) of heterozygous ela fish that were
selected and backcrossed at least five times before phenotypic
analysis was undertaken.
We analyzed three distinct ela alleles: elabr21, elabr13, and
elabr15. elabr21 is a 21 bp deletion that causes a unique 7 aa in-
frame deletion within the signal peptide but leaves the mature
peptide intact. elabr13 and elabr15 are frameshift alleles that are
caused by deletion of 13 and 15 bp, respectively, and disrupt
the entire mature Ela peptide (Figure 2D). ela null embryos devel-
oped normally up to 50% epiboly, after which migration anoma-
lies were observed in the germ ring. We easily scored ela null
embryos by eye using the ‘‘rough’’ and constricted appearance
of the involuting marginal layer at the shield stage (Figure 2E).
At 100% epiboly, when ela expression peaks (Figure 2B), we
confirmed by RT-PCR that elabr13 mRNA was shorter than
wild-type (WT) ela mRNA (Figure 2F), which is consistent with
its biallelic genomic deletion. By western blotting using a C anti-
bodies, we detected the endogenous Ela full-length protein in
extracts of WT embryos, but not in elabr13 embryos (Figure 2F).
Loss of ela Causes Embryonic Lethality Due to Heart
Dysgenesis
All ela homozygous mutant fish showed similar phenotypes and
were present in the expected Mendelian recessive ratios (Fig-
ure 3A and Figures S1A–S1C available online), suggesting that
the three alleles behave as loss-of-function mutants. ela hetero-
zygous fish were phenotypically normal, whereas ela null fish
presented with severe cardiac dysplasia ranging from a rudi-
mentary heart to no heart (Figures 3A, 3B, and S1A–S1C). Loss
or severe reduction of the embryonic heart marker cmlc1 was
seen in more than 95% of ela null embryos (n > 370) regardless
of the allele analyzed (Figure 3C). Furthermore, ela null embryos
had minimal blood circulation and we observed excess erythro-
cytes accumulating at the intermediate cell mass (ICM) (Fig-
ure 3A), as confirmed by scl upregulation in elamutant embryos
relative to heterozygous siblings (Figure 3D).
In addition, elamutant larvae displayed variable posterior trun-
cations and, at times, tailbud duplications. Posterior tissue de-
fects ranged from loss of the ventral fin to complete tail and trunk
truncations (Figure 3A). Unexpectedly, similar phenotypes were
also observed upon ela mRNA overexpression (Figure S1D).
Thousands of ela null embryos from all three genotypes were ob-
tained and scored into three classes according to the severity of
tail defects (Figures 3A and 3E). We observed that the relative
proportions of each class varied greatly among heterozygous
crosses (Figure 3E) and even among different clutches of em-
bryos born to identical parents (data not shown), suggesting a
notable phenotypic variance in tail development but not in heart
morphogenesis. Remarkably, a very low percentage of ela null
mutants developed to fertile adults (Figure 3F), ruling out any
maternal ela effects and permitting homozygous crosses to yield
100%null clutches. These three ela loss-of-function alleles show
that truncation of one-third of the Ela signal peptide results in
phenotypes identical to those caused by frameshift mutations,
indicating that Ela requires an intact signal peptide to be func-
tional in vivo. Moreover, these recessive ela alleles suggest
that reducing Ela levels by half is of no obvious consequence,
whereas a total absence of Ela is incompatible with heart devel-
opment, hematopoiesis, and, to a lesser extent, tail elongation.DevelopmeELA Is Required for Proper Endoderm Differentiation
In order to understand the embryological origin of the severe
cardiac defects observed in ela mutant fish, we analyzed by
whole-mount in situ hybridization (WISH) a series of markers
for all three embryonic germ layers. Most prominently, ela
mutant gastrulae displayed specific defects in the mesendo-
dermal lineage (Figures 3G–3L). Mesoderm marked by bra
exhibited impaired epiboly movements, presumably caused by
convergent-extension anomalies. At 100% epiboly, ela mutant
embryos were delayed and had an open blastopore with a
shorter and thicker notochord relative to WT embryos (Fig-
ure 3G). The expression of gata5, which marks mesendoderm
and promotes the development of cardiovascular progenitor
cells (CPCs), was distinctly altered in ela embryos compared
with WT embryos at 75% epiboly. Instead of marking a discrete
axial population of cells in the heart-forming region, ela null em-
bryos displayed a distinctive chevron shape around the orga-
nizer that was continuous with the marginal gata5-expressing
cells (Figure 3H). The expression of foxa2wasmarkedly reduced
in its marginal, but not axial, component, indicating a diminished
endoderm differentiation potential (Figure 3I) as confirmed by
the reduced expression of sox17 (Figure 3J), which marks the
definitive endodermal precursors. sox17 forerunner cells were
unaltered by the absence of ela, indicating specificity vis-a`-vis
the endoderm lineage. The total number of sox17+ cells at
75% epiboly were on average decreased by 30%–40%
compared with their WT or ela heterozygous siblings (Figure 3K),
similar to what was observed in homozygous elabr15 and elabr21
embryos (Figure 3L). We conclude that ela is essential in vivo for
the proper differentiation of endodermal precursors that are
known to be crucial for guiding the overlying cardiac progenitors
to the heart-forming region.
Aplnr Is the Cognate Receptor for Ela during Heart
Development
The elamutant phenotype bears a striking resemblance to that of
the apelin receptor (Aplnr), which has been implicated in heart
development. The zebrafish mutant grinch, which carries a
recessive W90L missense mutation in aplnrb, and Aplnr
knockout mice both have defects in cardiac morphogenesis
(Charo et al., 2009; Scott et al., 2007). Unexpectedly, however,
loss of Apelin (Apln), the accepted ligand for Aplnr, does not
recapitulate the phenotype of grinch in zebrafish or Aplnr null
mice. We thus surmised that Ela might be the long-sought-after
alternate and earlier ligand for Aplnr (Charo et al., 2009; Scott
et al., 2007). Unlike most other hormones that have near-neutral
isoelectric points, ELA and APLN are rich in basic residues and
have isoelectric points above 12 (Figure 4A), suggesting they
might share a common receptor. For Ela to be the earliest ligand
of Aplnr, we contended that it should (1) be expressed concom-
itantly with aplnr before the onset of gastrulation, (2) be ex-
pressed in or adjacent to aplnr-expressing cells, (3) phenocopy
aplnr mutants, and (4) bind to Aplnr on the surface of cells.
Consistent with previous reports, we found that the onset of
aplnra and aplnrb coincides with that of ela at MBT, whereas
apln expression begins 5 hr later during gastrulation (Figure 4B).
Cells expressing aplnra and aplnrb are in the hypoblast (Zeng
et al., 2007), just beneath the overlying enveloping layer where
ela is ubiquitously transcribed (Figure 2A). We found that thental Cell 27, 672–680, December 23, 2013 ª2013 Elsevier Inc. 675
Figure 3. ela Knockout Zebrafish Have Severe Cardiovascular and Endoderm Defects
(A) Null elabr21 larvae display pericardial edema (white arrowheads) and accumulated erythrocytes (red arrowheads), and have no blood circulation. Variable
posterior anomalies are observed, including loss of ventral fin (black arrowheads), tailbud duplications (inset), and extreme tail/trunk truncations (bottom embryo).
(B) Loss of ela causes severe cardiac anomalies ranging frommild heart dysplasia to total heart agenesis, as shown by hematoxylin and eosin staining on sections
from the top and bottom embryos in (A).
(C) Null elabr13 fish have a severe reduction of cmlc1 expression, which marks the developing heart.
(D) Null elabr13 fish display increased hematopoiesis as judged by the upregulation of scl, a marker of blood precursors.
(E) Classification of null elabr13 larvae with varying degrees of tail defects. Class I larvae are defined as having pericardial edema and tail blood clot. Class 2 larvae
have ventral fin defects or tailbud duplications in addition to class 1 phenotypes. Class 3 larvae have all phenotypes of class 1 combined with mild to severe tail/
trunk truncations.
(F) Percentages of ela mutant fertile adults that were obtained from heterozygous intercrosses using all three alleles.
(G) Relative to WT embryos, homozygous null elabr13 embryos show convergence-extension defects resulting in delayed blastopore closure and thickened
notochord (insets) as indicated by altered bra expression.
(H) The loss of ela causes defective migration of mediolateral gata5-expressing cells, which mark mesendoderm cells that guide heart progenitors to the anterior
lateral plate mesoderm.
(I) ela mutant embryos show reduced foxa2 expression compared with WT embryos.
(J) ela mutant embryos show a more compact sox17 expression pattern compared with WT embryos, whereas sox17+ forerunners cells are not affected.
(K) ela null embryos have approximately 40% less sox17+ cells than their heterozygous siblings at 75% epiboly.
(L) At 75% epiboly, elabr21 and elabr15 mutant embryos exhibit sox17 expression defects similar to those observed for elabr13 (see also Figure S1).
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Figure 4. Ela’s Cognate Receptor for Endoderm Differentiation Is Aplnr
(A) ELA and apelin are very basic hormones with isoelectric points exceeding 12.
(B) By qPCR, the onset of transcription of aplnra and aplnrb coincides with that of ela at the MBT; apln expression debuts 5 hr later during gastrulation (data are
represented as mean ± SEM).
(C) Relative to control embryos, the expression of aplnra and aplnrb at 70% epiboly becomes stronger and confined to the most equatorial hypoblast in the ela
mutant (white arrowheads: specific aplnra expression in the animal pole).
(D)WT embryo with a beating heart and blood circulation at 6 dpf, normal sox17 expression in definitive endoderm at 75% epiboly, no erythrocyte accumulation in
the ICM, and cmlc1 expression in the heart-forming region at 30 hpf.
(E) aplnrmorphants phenocopy elamutant embryos, with no beating heart, loss of blood circulation at 6 dpf, reduced sox17 expression in definitive endoderm at
75% epiboly, accumulation of erythrocytes in the ICM, and loss of cmlc1 expression in the heart-forming region at 30 hpf.
(F) elamutant embryos are nearly indistinguishable from Aplnrmorphants and have no beating heart or blood circulation at 6 dpf, show reduced sox17 expression
in definitive endoderm at 75% epiboly, have accumulated erythrocytes in the ICM, and no cmlc1 expression in the heart-forming region at 30 hpf.
(G) In 293T cells, overexpression of zebrafish aplnra or aplnrb, or human APLNR is sufficient to confer cell-surface binding to recombinant AP-ELA.
(H) In 293T cells, overexpression of zebrafish aplnrb, but not its mutant form (grinch) carrying the W90L missense mutation, or GPR15 (an orphan GPCR closely
related to APLNR), is enough to afford binding to recombinant AP-ELA.
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Ela, a Ligand for Aplnrexpression of aplnra and aplnrb was also responsive to the loss
of ela, displaying a more condensed pattern at the margin rela-
tive to WT embryos (Figure 4C). Using an array of markers, we
found that aplnr morphants were phenotypically indistinguish-
able from ela null embryos. Both exhibited pericardial edema
with markedly reduced cmlc1 expression and accumulation of
erythrocytes in the ICM at 30 hr postfertilization (hpf). By
6 days, all ela mutant and aplnr morphant embryos had cardiac
dysplasia with little to no blood circulation (Figures 4D–4F).
These in vivo data demonstrate that loss of ela phenocopies
the loss of aplnr, arguing that they form a ligand-receptor pair
in vivo. Lastly, overexpression of zebrafish Aplnra and Aplnrb
in human embryonic kidney 293T (HEK293T) cells was sufficient
to afford cell-surface binding to ELA conjugated to alkaline phos-
phatase (AP-ELA) (Figure 4G). In contrast, Aplnrbgrinch was un-
able to bind AP-ELA (Figure 4H). This interaction is conserved
across species, since overexpression of human APLNR also
confers binding to AP-ELA, but not GPR15 (Figure 4H), an
orphan GPCR that is closely related to APLNR (Vassilatis et al.,
2003). These results suggest that extracellular ELA can bind
APLNR in a native cellular context. Taken together, our results
support the notion that ELA, and not APLN, is the earliest agonist
of APLNR, which works in tandem to direct endodermal differen-
tiation for cardiac ontogeny.
DISCUSSION
We have uncovered a peptide hormone with potent embryonic
signaling activity. Encoded by a transcript that is believed to
be a long noncoding RNA, ELA is in fact the precursor for a small
secreted peptide that is found in all vertebrate species. In vivo,
ELA specifically affects the mesendodermal lineage, where its
activity, transduced by Aplnr, brings about the migration and
differentiation of the cardiac lineage.
Unannotated Hormones
We present evidence that uncharacterized peptide hormones
exist in the human genome and have yet to be annotated as
such. We surmise that more will surface as multiexonic tran-
scripts are screened for the existence of phylogenetically
conserved small ORFs. One such example is ELA, which up until
now has been annotated as a long noncoding RNA. Several ob-
servations may explain, at least in part, why such tiny peptides
are overlooked: (1) they are underrepresented in the proteome
and escape mass-spectrometric detection, (2) ORF prediction
algorithms are biased toward longer ORFs if phylogenetic
conservation is not taken into consideration, and (3) despite
evolutionary preservation, phylogenetic alignment may not be
sufficient to uncover these hormones, since signal peptides are
poorly conserved and only a portion of the mature peptide
involved in signaling might be invariant, as in the case of ghrelin
and bradykinin, which undergo further processing after secretion
(Kojima et al., 1999; Sheikh and Kaplan, 1989). In this regard, we
note the presence of two conserved di-arginine motifs in the ELA
mature peptide (R31R32 and R42R43), which could serve as
recognition and cleavage sites for furins (Hosaka et al., 1991).
If ELA is further processed by furin-like proteases, a C-terminal
11-mer fragment that is evolutionarily invariant (Figure 1A) may
be generated.678 Developmental Cell 27, 672–680, December 23, 2013 ª2013 ElsThe Ela-Aplnr Axis in Cardiovascular Development
Scott et al. (2007) have shown that although aplnr is required
prior to the onset of gastrulation for proper cardiac morphogen-
esis, its known ligand, apln, is not expressed until midgastrula-
tion. Similarly, several groups have reported that knockouts of
Apln andAplnr in mice are not functionally allelic, aswould be ex-
pected if a linear and exclusive ligand-receptor relationship
linked Apln to Aplnr (Charo et al., 2009). This led some investiga-
tors to hypothesize that Aplnr may have ligand-independent
functions, and recent reports have shown that Aplnr can respond
to stretch (Scimia et al., 2012). An alternate and nonmutually
exclusive explanation for this phenomenon invokes the exis-
tence of a second ligand for Aplnr. Our results suggest that Ela
fulfills this role in early zebrafish embryogenesis together with
Aplnr, to direct the migration and amplification of endodermal
precursors for proper cardiac ontogeny.
At present, it is unclear whether Apln and Ela signal through
Aplnr to elicit identical signaling cascades and therefore can
partly compensate for one another. With respect to cardiovas-
cular development, however, we note that apln zebrafish
morphants and apln mouse knockouts do not display overt
congenital cardiac anomalies (Kuba et al., 2007; Scott et al.,
2007). The Ela-Aplnr axis thus appears to be exclusive for car-
diac development, and Apln may be insufficient due either to
divergent signaling downstream of Aplnr or simply to incompat-
ible spatiotemporal patterns of expression.
How ela in the epibolyzing blastoderm affects the migration
and differentiation of aplnr-expressing endodermal precursors
in the hypoblast is not clear. Our analysis places ela upstream
of gata5, one of the earliest markers of mesendodermal cells,
which fails to coalesce at the midline in ela mutants. Mutation
in gata5 in faust zebrafish demonstrates that this transcription
factor is required for precardiac mesoderm to migrate to the em-
bryonic midline (Reiter et al., 1999). The myocardium lineage,
which is one of the first paraxial cell populations to migrate into
the anterior lateral plate mesoderm (ALPM), is very sensitive to
changes in the endoderm lineage, which is specified by the
Nodal pathway (Schier, 2003). Our loss-of-function alleles place
signaling by Ela upstream of or parallel to the endodermal-medi-
ated pathway for heart morphogenesis. Ela may be required for
the correct proliferation of endoderm precursor cells, as judged
by their decreased numbers in ela mutant fish. Alternatively, or
concurrently, Ela may behave as a chemotactic stimulus that
promotes the timely migration of endodermal cells toward the
midline, which in turn guide the CPCs toward the APLM and
render them competent to initiate cardiogenesis.
FUTURE DIRECTIONS
In addition to being expressed in hESCs, ELA mRNA is also
found in the adult human prostate and kidney. It will be inter-
esting to examine its role in these tissues. Although it is quite
speculative at this stage, several forward-looking statements
can bemadewith respect to the possible therapeutic value of re-
combinant ELA. Assuming that ELA signals through APLNR in
adults, it will be important to assess whether this hormone is en-
dowed with potent cardioprotective and vasodilatory properties,
as observed for APLN (Ashley et al., 2005; Maguire et al., 2009),
and therefore can serve as a therapeutic peptide for cardiacevier Inc.
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ELA may serve as a potent inducer of cardiac lineages in vitro,
and along this line, potential loss-of-function ELA alleles may
be associated with cardiovascular diseases in the general
human population. Coincidentally, since APLNR permits entry
of HIV-1 by serving as a coreceptor (Zou et al., 2000), recombi-
nant ELA may serve as a competitive inhibitor of HIV-1 when
APLNR is solicited for viral entry.
EXPERIMENTAL PROCEDURES
Accession Codes
The human ELABELA gene and its vertebrate homologs are accessible
with the following Ensembl IDs: Homo sapiens: ENSG00000248329; Mus
musculus: ENSMUSG0000007430; Gallus gallus: ENSGALG00000023444;
and Danio rerio: ENSDARG00000094729.
Antibodies and Recombinant Peptide
Polyclonal antibodies were raised against a human N-terminal epitope
(nh2-QRPVNLTMRRKLRKHNC), C-terminal epitope (CMPLHSRVPFP-cooh),
or whole mature ELABELA peptide (nh2-QRPVNLTMRRKLRKHNCLQRRCMP
LHSRVPFP-cooh) and peptide-affinity purified from rabbit sera. For western
blotting, ELA antibodies were used at 1 mg/ml. a TGN-46 was purchased from
Serotec (#AHP500GT). Recombinant mature ELA was synthetically produced
and consists of the last 32 aa of ELA.
Developmental RT-PCR and Quantitative PCR Analysis
Total RNA was extracted from a group of 30 embryos at the designated stage
using RNA Easy Kit (QIAGEN). cDNAs were synthesized from 1 mg of total RNA
using random hexamers (Promega) and Superscript III reverse transcriptase
(Invitrogen). RT-PCR was performed for 24 cycles and zebrafish actin was
used as a loading control. Quantitative PCR (qPCR), normalized to actin
expression levels, was performed with the SYBR Green Master Mix (Roche).
The reactions were carried out in triplicate for each experiment and data
were expressed as means ± SE. All qPCR primers used are listed in Supple-
mental Experimental Procedures.
Cell Culture and Immunofluorescence
The Shef4 cell line was used and exhibited the standard morphological and
surface marker characteristics of hESCs and a normal 46XY karyotype
(Inniss and Moore, 2006). Feeder-free hESCs were cultured in mTSER1
(Stem Cell Technologies) on Matrigel (BD 354277). For immunofluorescence,
hESCs were dissociated and plated onto Matrigel-coated chamber slides
(Millipore) and cultured for 48 hr. Cells were fixed with 4% paraformaldehyde
in PBS for 20 min at room temperature, permeabilized in 0.5% Triton X-100
with 5% fetal calf serum in PBS, and stained overnight with a C antibody at
1 mg/ml.
Embryological Methods
The protocols used for fertilization, microinjections, secretion assay, and
WISH are available at our protocol website (http://www.reversade.com-a.
googlepages.com/protocols/). Zebrafishweremaintained and used according
to guidelines approved by the Singapore National Advisory Committee on Lab-
oratory Animal Research. ZFNs were purchased from Sigma-Aldrich, and 250
pg of mRNAs encoding the ZFN pair was injected into 1-cell-stage embryos.
The ZFN-binding sites within exon 1 are as follows: 50_TCCACCCGCTGTA
TCT_30 and 50_GCTGCTGCTGACAGT_30. The sequencing primers flanking
the mutation sites are as follows: forward 50_AACACTTGCTGAGAGCGA
CAG_30, reverse 50_AGATGTGGTGGTGTTGAGTAGC_30. For ela overexpres-
sion, 200 pg of SP6-transcribed zebrafish ela capped mRNA (Applied
Biosystems) was injected into 1-cell-stage zebrafish embryos. The transla-
tion-blocking morpholino oligonucleotides (MOs) used for aplnra and aplnrb
have been described previously (Scott et al., 2007; Zeng et al., 2007) and
were purchased from Gene Tools. Embryos were injected at the 1-cell stage
with a combination of 1 ng of aplnra MO and 0.5 ng of aplnrb MO (Zeng
et al., 2007). Information on the probes used for WISH can be found in the Sup-Developmeplemental Experimental Procedures. Zebrafish embryos at 100% epiboly were
dechorionated and processed for western blotting as previously described
(Link et al., 2006). For the Xenopus secretion assay, 16 ng of SP6-transcribed
human ELA capped mRNA (Applied Biosystems) was injected into each cell of
4-cell-stage embryos. At stage 8, the embryos were dechorionated and disso-
ciated in calcium magnesium-free medium (CMFM) with 5 mM EDTA. Cell pel-
lets of ten embryos were transferred into 1.5 ml tubes and allowed to secrete
for 24 hr at room temperature in 40 ml of fresh CMFM medium with or without
BFA. The conditioned supernatant was carefully depleted of all cells before
SDS-PAGE electrophoresis was conducted on 16.5% Tris-Tricine precast
gels (BioRad).
AP-ELA Binding Assay
An AP-ELA fusion construct was generated by cloning the mature C-terminal
32-mer of ELA in frame with the carboxy terminus of the AP ORF, which con-
tained an N-terminal signal sequence from Xenopus chordin (Reversade and
De Robertis, 2005). This construct was transfected into 293T cells with Fugene
HD (Promega) and allowed to secrete for 48 hr into serum-free media (Pro293a
CDM; Lonza). The resulting supernatant was incubated with test cells for 3 hr,
washed three times with PBS, lysed, and heated at 65C to inactivate endog-
enous APs. Lysates were then incubated with BM Purple (Roche) at 37C for
chromogenic development.
DNA Constructs and Site-Directed Mutagenesis
Zebrafish aplnra, aplnrb, and elabela ORFs were cloned from 80% epiboly
cDNA into vector pCS2+ between restriction sites BamHI and XbaI. Human
APLNR and GPR15 ORFs were cloned from human genomic DNA into
pCS2+ between restriction sites BamHI and XbaI. The primers used for ampli-
fication are listed in the Supplemental Experimental Procedures. aplnrbgrinch
(W90L) was generated using the QuikChange Site-Directed Mutagenesis kit




Supplemental Information includes Supplemental Experimental Procedures
and one figure and can be found with this article online at http://dx.doi.org/
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